Invitae provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated with cancer, cardiology, neurology and pediatrics. It will use the new capital to accelerate the build out of its infrastructure, as well as to expand its global presence.
With all the talk about seed and Series A venture financings lately, let's not forget about the big guys—the late stage rounds. Venture capital invested in Series E or later rounds has increased significantly each of the last two years, according to the PitchBook Platform, with 2014 ($7.4 billion invested) already more than doubling 2012's total ($3.4 billion). The median deal size has also soared during that timeframe, climbing from $17.3 million in 2012 to $21.4 million in 2013 to $30 million so far this year.
Some very notable companies have fed this trend, including:
For more details on the companies listed—including deal history, valuations, investors and more—or to see the rest of the companies that have raised Series E+ VC funding, click here to dive into the PitchBook Platform.